Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Change in Account Payables (2016 - 2025)

IGC Pharma (IGC) has disclosed Change in Account Payables for 16 consecutive years, with -$303000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables fell 15050.0% to -$303000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$142000.0, a 164.55% decrease, with the full-year FY2025 number at $106000.0, down 56.38% from a year prior.
  • Change in Account Payables was -$303000.0 for Q3 2025 at IGC Pharma, down from $51000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $773000.0 in Q1 2021 to a low of -$675000.0 in Q4 2021.
  • A 5-year average of $16111.1 and a median of $47500.0 in 2025 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 2650.0% in 2025; the steepest drop was 15050.0% in 2025.
  • IGC Pharma's Change in Account Payables stood at -$675000.0 in 2021, then soared by 101.19% to $8000.0 in 2022, then skyrocketed by 1125.0% to $98000.0 in 2023, then plummeted by 32.65% to $66000.0 in 2024, then plummeted by 559.09% to -$303000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Change in Account Payables are -$303000.0 (Q3 2025), $51000.0 (Q2 2025), and $44000.0 (Q1 2025).